MindTree Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of MindTree Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: MindTree Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news and updates on MindTree Ltd. from all sources in a single place.

Load latest

MindTree Ltd.

18 Apr 2022

Corp. Action

MINDTREE LTD. - 532819 - Corporate Action-Board approves Dividend

BSE India

The Board of Directors of the Company at its meeting held today, April 18, 2022 recommended a Final Dividend of 270% (Rs.27/- per equity share of face value of Rs.10/- each) for the financial year ended March 31, 2022. The Final Dividend is subject to the approval of Shareholders at the Twenty Third Annual General Meeting

pdf

MindTree Ltd.

18 Apr 2022

Result

MINDTREE LTD. - 532819 - Audited Financial Results For The Fourth Quarter And Financial Year Ended …

BSE India

Audited Financial Results for the fourth quarter and financial year ended March 31, 2022 and recommendation of Final Dividend

pdf

MindTree Ltd.

18 Apr 2022

Company Update

MINDTREE LTD. - 532819 - Clarification sought from MindTree Ltd

BSE India

The Exchange has sought clarification from MindTree Ltd on April 18, 2022, with reference to news appeared inwww.livemint.com dated April 18, 2022 quoting "L&T Infotech, Mindtree to merge to create $22-bn entity."The reply is awaited.

MindTree Ltd.

18 Apr 2022

Annual Report

Annual report for MindTree Ltd. for FY-2022

None

pdf

MindTree Ltd.

18 Apr 2022

Mindtree (BUY): In-line quarter; robust TCV a key positive

Buy: MindTree Ltd.

BOB Capital Markets Ltd.

Q4 revenue growth at 4.8% QoQ USD was largely in line with our estimate, driven by travel and BFSI verticals; manufacturing and retail slowed

BOB Capital Markets Ltd. downgraded MindTree Ltd. to Sell with a price target of 3837.0 on 24 Apr, 2025.

MindTree Ltd.

18 Apr 2022

Reassuring performance, valuations full

Neutral: MindTree Ltd.

Target

Motilal Oswal

MTCL reported a revenue of USD384m (+5.2% QoQ CC) in 4QFY22. Reported revenue grew 4.8% (inline), driven by broad-based growth across verticals and regions. Deal TCV rose 9% QoQ to USD390m in 4QFY22. The management reiterated that the demand environment continues to remain strong, and expects industry-leading growth in FY23. EBITDA margin fell 50bp QoQ (inline) in 4QFY22 on higher utilization and...

BOB Capital Markets Ltd. downgraded MindTree Ltd. to Sell with a price target of 3837.0 on 24 Apr, 2025.

MindTree Ltd.

13 Apr 2022

Mindtree Q4 PAT may dip 0.6% QoQ to Rs. 434.7 cr: Prabhudas Lilladher

Moneycontrol

Net Sales are expected to increase by 5.2 percent Q-o-Q (up 37.1 percent Y-o-Y) to Rs. 2,891.8 crore, according to Prabhudas Lilladher.

BOB Capital Markets Ltd. downgraded MindTree Ltd. to Sell with a price target of 3837.0 on 24 Apr, 2025.

MindTree Ltd.

12 Apr 2022

Company Update

MINDTREE LTD. - 532819 - Statement Of Investor Complaints For The Quarter Ended March 2022

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 111120 Name of the Signatory :- Subhodh ShettyDesignation :- Company Secretary and Compliance Officer

MindTree Ltd.

07 Apr 2022

Company Update

MINDTREE LTD. - 532819 - Compliance Certificate As Per Regulation 40(9) For The Year Ended March …

BSE India

Compliance Certificate as per Regulation 40(9) for the year ended March 31, 2022

pdf

MindTree Ltd.

05 Apr 2022

Company Update

MINDTREE LTD. - 532819 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Strategic Investment in COPE Healthcare Consulting Inc., - Mindtree Limited (Mindtree) has made a strategic investment and agreed to acquire a 6.64% stake in COPE Healthcare Consulting Inc., USA pursuant to a Stock Purchase Agreement entered on April 4, 2022.

pdf

Is MindTree Ltd. worth buying?

321 Votes:

Buy 69.47%

Sell 19.0%

Hold 11.53%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf